March 15, 2010 — The US Food and Drug Administration (FDA) has approved a twice-yearly 22.5-mg formulation of triptorelin pamoate injection (Trelstar, Watson Pharmaceuticals, Inc) for the palliative ...
Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...
Triptodur, a gonadotropin-releasing hormone (GnRH) agonist, is given as an intramuscular (IM) injection every 6 months. Arbor and Debiopharm announced the launch of Triptodur (triptorelin ...
Details concerning the Triptorelin Pamoate for Injectable Suspension medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ...
This medication is a synthetic analogue of gonadotropin-releasing hormone (GnRH) agonist, prescribed for prostate cancer.
Triptodur™, (triptorelin) for extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty with once every six-month intramuscular injection (IM) dosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results